Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.22 and traded as low as $7.00. Arcturus Therapeutics shares last traded at $7.02, with a volume of 484,139 shares changing hands.

Analysts Set New Price Targets

A number of research analysts recently commented on ARCT shares. Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, October 23rd. Piper Sandler dropped their price target on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Guggenheim cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Zacks Research lowered Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Finally, BTIG Research reduced their price target on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.00.

Arcturus Therapeutics Stock Down 4.2%

The company has a market cap of $199.44 million, a price-to-earnings ratio of -2.85 and a beta of 2.39. The business has a 50-day simple moving average of $6.97 and a two-hundred day simple moving average of $12.22.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.60. The business had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%. As a group, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. raised its holdings in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 738 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA acquired a new position in shares of Arcturus Therapeutics in the third quarter valued at $111,000. CANADA LIFE ASSURANCE Co lifted its position in Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 2,313 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.